Emil Lou, MD, PhD
- Gastrointestinal Cancer
- Brain Cancer
- Masonic Cancer Clinic
State University of New York (SUNY) Upstate Medical University, Syracuse, NY
Duke University Medical Center, Durham, NC (Internal Medicine)
Memorial Sloan-Kettering Cancer Center, New York, NY (Medical Oncology and Hematology)
The Preston Robert Tisch Brain Tumor Center at Duke, Duke University Medical Center, Durham, NC (Neuro-Oncology)
P: (612) 624-0123
F: (612) 625-6919
Patient Related Information
For any patient-related correspondence, please use the following address:
Masonic Cancer Clinic
First Floor, Suite M100
424 Harvard St SE
Minneapolis, MN 55455
Emil Lou Fairview Contact
P: (612) 625-5411
F: (612) 625-6137 to reach the Main Clinic
F: (612) 626-9862 to reach New Patient Scheduling
Division of Hematology, Oncology and Transplantation
420 Delaware Street SE, MMC 480
Minneapolis, MN 55455
After completing undergraduate studies in biochemistry at SUNY College at Geneseo, Dr. Lou received his M.D. and Ph.D. degrees (Microbiology and Immunology) from SUNY Upstate Medical University in 2004. He performed his residency training in Internal Medicine at Duke University Medical Center and then subsequently completed his Medical Oncology and Hematology fellowship at the Memorial Sloan-Kettering Cancer Center in 2010. He also completed an additional fellowship in Neuro-Oncology at the Preston Robert Tisch Brain Tumor Center at Duke.
Dr. Lou, a diplomate of the American Board of Internal Medicine, is board certified in Medical Oncology and Internal Medicine. He joined the faculty in the Division of Hematology, Oncology and Transplantation in 2011 and is a member of the Masonic Cancer Center, University of Minnesota.
- ASCO Scientific Program Committee Member, Gastrointestinal (Noncolorectal) Cancer track (2012-2015)
- Scientist Mentor, AACR Scientist <--> Survivor Program (2013 and 2014)
- Graduate Program Faculty Member, Integrative Biology and Physiology (IBP) Program
- Member, American Association for Cancer Research
- Member, American Society of Clinical Oncology
- Member, Masonic Cancer Center, University of Minnesota
- Research Program Member, UMN Tumor Microenvironment Program, Masonic Cancer Center
- Distinguished Alumnus, State University of New York (SUNY) Upstate Medical University (2014)
- KL2 Scholar, KL2 Scholars Career Development Program, Clinical and Translational Science Institute (CTSI), University of Minnesota (2013 - 2016)
- Conquer Cancer Foundation Oncology Trainee Travel Award. American Society of Clinical Oncology (2011)
- AACR-GlaxoSmithKline Clinical Scholars Award (2010)
- AACR-Aflac, Inc. Scholar-in-Training Award, American Association for Cancer Research (2007)
- John Bernard Henry Endowed Fellowship Award, SUNY Upstate Medical University (2004)
- American Head and Neck Society Trainee Award (2002)
- E Lou, KP Peters, AL Sumrall, A Desjardins, DA Reardon, ES Lipp, JE Herndon II, A Coan, L Bailey, S Turner, HS Friedman, JJ Vredenburgh. Phase II trial of upfront Bevacizumab and Temozolomide for unresectable or multifocal glioblastoma. Cancer Medicine 2(2): 185-95, April 2013; Epub January 24, 2013.
- Lou E, Fujisawa S, Barlas A, Romin Y, Manova-Todorova K, Moore MAS, Subramanian S. Tunneling Nanotubes: A new paradigm for studying intercellular communication and therapeutics in cancer. Communicative & Integrative Biology 5(4), July/August 2012.
- Lou E, Sumrall A, Turner S, Peters K, Desjardins A, Vredenburgh JJ, McLendon R, Herndon JE II, McSherry F, Norfleet J, Friedman HS, Reardon DA. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. Journal of Neuro-Oncology, published online April 26 2012 (Epub ahead of print).
- Lou E, Fujisawa S, Morozov A, Barlas A, Romin Y, Dogan Y, Moreira AL, Manova-Todorova K, Moore MAS. Tunneling nanotubes provide a unique conduit for Intercellular transfer of cellular contents in human malignant pleural mesothelioma. PLoS ONE 7(3): e33093. doi:10.1371/journal.pone.0033093. March 9, 2012.
- Reardon DA, Herndon JE 2nd, Peters K, Desjardins A, Coan A, Lou E, Sumrall A, Turner S, Sathornsumetee S, Rich JN, Boulton S, Lipp ES, Friedman HS, Vredenburgh JJ. Outcome after bevacizumab clinical trial therapy among recurrent grade III malignant glioma patients. J Neurooncol. 2011 Oct 14.
- Lou E, Turner S, Sumrall A, Reardon DA, Desjardins A, Peters KB, Sampson JH, Friedman HS, Vredenburgh JJ. Bevacizumab-induced reversible posterior leukoencephalopathy syndrome and successful retreatment in a patient with glioblastoma. J Clin Oncol. 2011 Oct 1;29(28):e739-42.
- Morozov A, Downey RJ, Healey J, Moreira AL, Lou E, Franceschino A, Dogan Y, Leung R, Edgar M, LaQuaglia M, Maki RG, Moore MA. Benign mesenchymal stromal cells in human sarcomas. Clin Cancer Res. 2010 Dec 1;16(23):5630-40.
- Lou E, Züchner S, Vance J, Morgenlander J. A potential novel variant of hereditary sensory neuropathy in a 61-year-old man with cough-induced syncope and vertebral artery dissection. Mayo Clin Proc. 2010 Jun;85(6):594-5.
- Lou E, Hensley ML, Lassman AB, Aghajanian C. Paraneoplastic opsoclonus-myoclonus syndrome secondary to immature ovarian teratoma. Gynecol Oncol. 2010 May;117(2):382-4. Epub 2010 Feb 7.
- Girard N, Lou E, Azzoli CG, Reddy R, Robson M, Harlan M, Orlow I, Yatabe Y, Ladanyi M, Viale A, Kris MG, Riely G, Miller V, Klein RJ, Matsuo K, Pao W. Analysis of genetic variants in never-smokers with lung cancer facilitated by an Internet-based blood collection protocol: a preliminary report. Clinical Cancer Research, 16(2):755-63 (Epub 2010 Jan 12), January 15, 2010.
- Lou E, Goodwin J, Howell DN, Hicks J, Caram LB. A G-CSF-secreting adrenal carcinoma with rhabdoid-like differentiation causing leukocytosis. Nat Rev Urol. 2009 Jul;6(7):392-7.
- V Thayanithy, EL Dickson, C Steer, S Subramanian, E Lou. Tumor-stromal cross talk: direct cell-to-cell transfer of oncogenic microRNAs via tunneling nanotubes. Translational Research, Epub ahead of print May 24, 2014.